#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Philadelphia chromosome positive Transitional cell cancer of the renal pelvis and ureter Encephalopathy neonatal Extra-osseous Ewing's sarcoma Microscopic polyangiitis Hereditary haemorrhagic telangiectasia Homocystinuria Small intestine leiomyosarcoma Myocarditis Neonatal alloimmune thrombocytopenia Loeys-Dietz syndrome Epstein-Barr virus associated lymphoproliferative disorder Factor VIII deficiency Dilated cardiomyopathy Bone marrow disorder More trials…

    Learn about Rare Diseases

    Angelman’s syndrome – Trials in Disease Netherton’s syndrome – Basic Information Mucopolysaccharidosis II – Diagnostics Haemophilia A without inhibitors – Diagnostics Propionic acidaemia Rhabdomyosarcoma recurrent – Life with Disease Angelman’s syndrome – Life with Disease Richter’s syndrome – Treatment Niemann-Pick disease – Treatment Arterial tortuosity syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Betula Verrucosa (108) Meropenem OMEGA-3-ACID ETHYL ESTERS 90 Bidridistrogene Xeboparvovec Abc-24F-116 Abacavir Epinephrine Daxdilimab F770/05 Lsta1 Tezacaftor Vibegron Nacystelyn Moxifloxacin Hhalpc Interferon Beta-1B Etamsylate Atropine Sulfate Belinostat Avibactam Sodium More therapies…

    Learn about Your Condition

    Haematological infection Vertigo Phaeochromocytoma Muscle strain Incontinence Barrett's oesophagus Fibrous dysplasia of bone Craniosynostosis Aneurysm ruptured Haemoglobinuria VEXAS syndrome Supraventricular tachycardia Vertebrobasilar stroke Skin candida Osteomyelitis acute More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hepatocellular carcinoma

  • Study of Tislelizumab immunotherapy in patients with liver cancer (hepatocellular carcinoma) who have moderately impaired liver function (Child-Pugh B)

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Tislelizumab
    France

  • Study of Lenvatinib for Patients with Poor-Prognosis Hepatocellular Carcinoma Undergoing Percutaneous Ablation Therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Lenvatinib
    France

  • Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Bevacizumab
    • Atezolizumab
    Austria France Germany Italy Spain

  • Study on the Safety and Effectiveness of Patritumab Deruxtecan for Patients with Colorectal, Biliary Tract, and Liver Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Bile duct cancer
    • Hepatocellular carcinoma
    • Colorectal cancer
    Investigated Drugs:
    • Patritumab Deruxtecan
    France Italy Spain

  • Study of Durvalumab and Tremelimumab for Patients with Resectable Liver Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Tremelimumab
    • Durvalumab
    Italy Spain

  • Study on Atezolizumab and Bevacizumab for Patients with Small Hepatocellular Carcinoma Undergoing Radiofrequency Ablation

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Bevacizumab
    • Atezolizumab
    France
Previous Page
1 2 3 4 5 6 … 15
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!